Bayesian‐optimized deep learning for identifying essential genes of mitophagy and fostering therapies to combat drug resistance in human cancers
Journal of Cellular and Molecular Medicine · 2025
DOI: 10.1111/jcmm.18254 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Cellular and Molecular Medicine, 2025. Verfasst von Wenyi Jin und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Orthopedics, Renmin Hospital of Wuhan University, Wuhan, China. Hauptthemen laut MEDLINE: Mitophagy, Drug Resistance, Neoplasm, Deep Learning, Osteosarcoma. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Hubei Provincial Key Research and Development Program.
Abstract (Originalsprache)
Dysregulated mitophagy is essential for mitochondrial quality control within human cancers. However, identifying hub genes regulating mitophagy and developing mitophagy‐based treatments to combat drug resistance remains challenging. Herein, BayeDEM (Bayesian‐optimized Deep learning for identifying Essential genes of Mitophagy) was proposed for such a task. After Bayesian optimization, BayeDEM demonstrated its excellent performance in identifying critical genes regulating mitophagy of osteosarcoma (area under curve [AUC] of ROC: 98.96%; AUC of PR curve: 100%). CERS1 was identified as the most essential gene regulating mitophagy (mean (|SHAP value|): 4.14). Inhibition of CERS1 sensitized cisplatin‐resistant osteosarcoma cells to cisplatin, restricting their growth, proliferation, invasion, migration and colony formation and inducing apoptosis. Mechanistically, inhibition of CERS1 restricted mitophagy to destroy the mitochondrial quality control in cisplatin‐resistant osteosarcoma cells, including mitochondrial membrane potential loss and unfavourable mitochondrial dynamics, rendering them susceptible to cisplatin‐induced apoptosis. More importantly, mitophagy facilitated the immunosuppressive microenvironment formation by significantly modulating T‐cell differentiation, adhesion and antigen presentation, and mitophagy mainly affects malignant osteoblasts in the early‐mid developmental stage. Immunologically, mitophagy potentially modulated the MIF signalling transmission between malignant osteoblasts and B cells, DCs, CD8+ T cells, NK cells and monocytes through the MIF‐(CD74 + CXCR4) receptor–ligand interaction, thereby modulating the biological functions of these immune cells. Collectively, BayeDEM emerged as a promising tool for oncologists to identify pivotal genes governing mitophagy, thereby enabling mitophagy‐centric therapeutic strategies to counteract drug resistance.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Orthopedics, Renmin Hospital of Wuhan University, Wuhan, China.
- Department of Biomedical Sciences, City University of Hong Kong, Hong Kong, China.
- Department of General, Visceral and Transplant Surgery, Ludwig-Maximilians-University Munich, Munich, Germany.
Förderung
- National Natural Science Foundation of China
- Hubei Provincial Key Research and Development Program
Zitieren
APA
Jin, W., Chen, J., Li, Z., Yubiao, Z., & Peng, H. (2025). Bayesian‐optimized deep learning for identifying essential genes of mitophagy and fostering therapies to combat drug resistance in human cancers. Journal of Cellular and Molecular Medicine. https://doi.org/10.1111/jcmm.18254
Vancouver
Jin W, Chen J, Li Z, Yubiao Z, Peng H. Bayesian‐optimized deep learning for identifying essential genes of mitophagy and fostering therapies to combat drug resistance in human cancers. Journal of Cellular and Molecular Medicine. 2025. doi:10.1111/jcmm.18254
BibTeX
@article{Jin2025,
author = {Jin, Wenyi and Chen, Junwen and Li, Zhongyi and Yubiao, Zhang and Peng, Hao},
title = {Bayesian‐optimized deep learning for identifying essential genes of mitophagy and fostering therapies to combat drug resistance in human cancers},
journal = {Journal of Cellular and Molecular Medicine},
year = {2025},
doi = {10.1111/jcmm.18254}
}
EUVIMED